Compare RAIL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | ZNTL |
|---|---|---|
| Founded | 1901 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.6M | 162.5M |
| IPO Year | N/A | 2020 |
| Metric | RAIL | ZNTL |
|---|---|---|
| Price | $13.54 | $2.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 134.0K | ★ 844.7K |
| Earning Date | 03-11-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $513,120,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.34 | N/A |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.31 | $1.01 |
| 52 Week High | $13.74 | $3.95 |
| Indicator | RAIL | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 67.03 | 49.28 |
| Support Level | $11.41 | $2.21 |
| Resistance Level | $12.87 | $2.51 |
| Average True Range (ATR) | 0.82 | 0.28 |
| MACD | 0.13 | -0.09 |
| Stochastic Oscillator | 90.35 | 20.83 |
FreightCar America Inc is a manufacturer of railcars and components, serving diverse transportation needs in North America. The company designs and produces a wide range of railcar types, including box cars, hoppers, covered hoppers, gondolas, and flat cars for both intermodal and non-intermodal freight. The company has two segments: The Manufacturing segment encompasses new railcar manufacturing, used railcar sales, leasing, and rebuilds, while the Aftermarket segment includes the selling of forged, cast and fabricated railcar parts and supplies for all railcar types, and provides aftermarket services including safety training, railcar inspections, and preventative maintenance. The company's revenue is predominantly derived from its Manufacturing segment.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.